0001415889-24-010433.txt : 20240405 0001415889-24-010433.hdr.sgml : 20240405 20240405165541 ACCESSION NUMBER: 0001415889-24-010433 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240403 FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Farzan Nima CENTRAL INDEX KEY: 0001808296 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39743 FILM NUMBER: 24827214 MAIL ADDRESS: STREET 1: C/O KEROS THERAPEUTICS, INC. STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kinnate Biopharma Inc. CENTRAL INDEX KEY: 0001797768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824566526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8582994699 MAIL ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-04052024_040430.xml X0508 4 2024-04-03 1 0001797768 Kinnate Biopharma Inc. KNTE 0001808296 Farzan Nima 800 WEST EL CAMINO REAL SUITE 180 MOUNTAIN VIEW CA 94040 true true false false CHIEF EXECUTIVE OFFICER 0 Common Stock 2024-04-03 4 D 0 2186 D 0 D Stock Option (right to buy) 2.57 2024-04-03 4 D 0 1281642 D 2030-03-23 Common Stock 1281642 0 D Stock Option (right to buy) 5.63 2024-04-03 4 D 0 437413 D 2030-08-18 Common Stock 437413 0 D Stock Option (right to buy) 35.38 2024-04-03 4 D 0 275000 D 2031-02-12 Common Stock 275000 0 D Stock Option (right to buy) 10.03 2024-04-03 4 D 0 400000 D 2032-02-11 Common Stock 400000 0 D Stock Option (right to buy) 6.78 2024-04-03 4 D 0 750000 D 2033-02-10 Common Stock 750000 0 D Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR. This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option. This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. /s/ James P. Reilly, Attorney-in-Fact 2024-04-05